Centiva Capital’s Design Therapeutics DSGN Stock Holding History

Centiva Capital’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-23,572	Closed	-$136K	–	1699
2023 Q1	$136K	Buy	+23,572	New	+$176K	﹤0.01%	1301

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Centiva Capital's DSGN Position: Q2 2023 in Review

Centiva Capital sold out of Design Therapeutics (DSGN) in Q2 2023, closing a stake of 23,572 shares — an estimated $136K sold.

Centiva Capital first reported a position in DSGN in Q1 2023 and held it in 1 quarter. The position peaked at $136K in Q1 2023. 97 funds tracked by Wall St. Rank hold DSGN as of Q2 2023.

Centiva Capital reported no remaining Design Therapeutics position as of Q2 2023 after selling out during the quarter.
Centiva Capital sold 23,572 Design Therapeutics shares in Q2 2023, an estimated $136K.
Centiva Capital first reported a position in Design Therapeutics in Q1 2023 and held it in 1 quarter.
Centiva Capital's Design Therapeutics position peaked at $136K in Q1 2023.
97 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.